115
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Investigation of the mutagenic and genotoxic activities of LLL-3, a STAT3 inhibitor

, , , &
Pages 30-35 | Received 30 Sep 2015, Accepted 15 Mar 2016, Published online: 10 Apr 2016
 

Abstract

LLL-3, an anthracene derived compound, has been shown to be a promising therapeutic agent for the treatment of some kinds of cancer such as chronic myeloid leukemia and glioblastoma. However, no data regarding the toxic properties of this compound have yet been described in the literature. The present work aimed to investigate the mutagenic and genotoxic activities of LLL-3 using the TA97, TA98, TA100, TA102 and TA104 Salmonella/microsome strains for the Ames test and the micronucleus assay with the mouse macrophage cell line RAW 264.7. The findings showed that LLL-3, at doses of 0.001, 0.01, 0.1, 1.0 and 10.0 μg/plate, did not induce mutagenic activity in the Salmonella strains used under the conditions tested, and nor did it present genotoxicity in RAW 264.7 cells, at 10.0, 100.0 and 1000.0 μg/mL doses. Moreover, it is important to point out that the mitotic index of the cells decreased after exposure to LLL-3 under the same conditions tested, which may suggest some cytostatic effect, since this compound acts by inhibiting STAT3. Since most drugs used in the treatment of cancer present mutagenic activity as an adverse effect, these results suggest that LLL-3 is a promising drug for cancer therapy.

Acknowledgements

The authors are grateful to Dr Pui-Kai Li (School of Pharmacy, Ohio State University) for kindly providing the LLL-3 compound.

Declaration of interest

The authors declare there were no conflicting interests. This research was supported by the Carlos Chagas Filho Research Support Foundation of the State of Rio de Janeiro (FAPERJ) and the National Council for Scientific and Technological Development (CNPq).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.